DIAMEDICA THERAPEUTICS INC (DMAC) Stock Analyst Ratings
USA - NASDAQ:DMAC - CA25253X2077 - Common Stock
6.96 USD
-0.11 (-1.56%)
ChartMill assigns a Buy % Consensus number of 82% to DMAC. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 12.58. This target is 80.75% above the current price.
DMAC was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about DMAC.
In the previous month the buy percentage consensus was at a similar level.
DMAC was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-18 | Lake Street | Maintains | Buy -> Buy |
| 2025-07-18 | Craig-Hallum | Maintains | Buy -> Buy |
| 2025-07-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-07 | HC Wainwright & Co. | Initiate | Buy |
| 2024-08-16 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-21 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-21 | Craig-Hallum | Maintains | Buy -> Buy |
| 2023-06-22 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2022-07-07 | Lake Street | Maintains | Buy |
| 2022-07-07 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-07-07 | Craig-Hallum | Maintains | Buy |
| 2021-06-30 | Roth Capital | Maintains | Buy |
| 2021-04-08 | Oppenheimer | Initiate | Outperform |
| 2021-02-17 | Roth Capital | Initiate | Buy |